The U.S. Food and Drug Administration (FDA) has finalized its guidance concerning cybersecurity in medical devices, as per a recent publication on JDSupra. This guidance, titled “Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions,” primarily provides advice to medical device manufacturers on heightening cybersecurity measures. This move comes as a response to the rapid evolution of online threats to patients and hospitals alike.
This guidance aims to ensure the creation of comprehensive and effective cybersecurity measures as part of quality assurance during the production of medical devices. This should be done prior to introducing the device into the market. Specifically, medical device manufacturers are required to consider many aspects of cybersecurity throughout the device development process, such as including robust controls of access, ensuring the integrity of data, maintaining system confidentiality and assuring system functionality.
The finalized version of the guidance exhibits several notable changes from the draft issued last year. Among these alterations is the addition of PATCH Act language. The PATCH (Protecting Access to Care Through Cybersecurity) Act specifies how companies should manage cyber hygiene, mitigating risk and effectively reacting to vulnerabilities. This inclusion underlines the urgency to prioritize seamless ways to manage cyber threats in healthcare situations.
It is crucial for legal professionals working with medical device manufacturing companies to acknowledge and adapt to this newly finalized guidance. It carries significant implications for the cybersecurity plans that companies must now devise and implement in their pre-market submissions for new devices. More importantly, it presents an opportunity for the users of these devices to be more secure and reassured about the cybersecurity efforts made to protect their health data.